SCHEMBL20202563

SCHEMBL20202563

Cc1ccc(C(C(C)C)n2nc(COCc3ccccc3)c(C(N)=O)c2N)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.60
RET P07949 3/20 0.38
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
NPY1R P25929 1/20 0.36
MAOB P27338 1/20 0.36
ADORA2A P29274 1/20 0.36
RECQL P46063 1/20 0.36
NPY2R P49146 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
XIAP P98170 1/20 0.35
GHSR Q92847 5/20 0.35
ALOX5 P09917 2/20 0.34
MAPK1 P28482 1/20 0.33
F2 P00734 1/20 0.33
POLB P06746 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18283117 0.90 PDE2A (0.69) PDE2ARETKDM4EALDH1A1MAPT
SCHEMBL20185343 0.87 PDE2A (0.61) PDE2ARETALDH1A1RECQL
SCHEMBL20202564 0.83 PDE2A (0.55) PDE2ARETKDM4EALDH1A1MAPT
SCHEMBL20202565 0.83 PDE2A (0.54) PDE2ARETKDM4EALDH1A1MAPT
SCHEMBL20581431 0.81 PDE2A (0.74) PDE2ARETKDM4EALDH1A1XIAP
SCHEMBL24211353 0.80 PDE2A (0.65) PDE2ARETXIAPGHSRALOX5
SCHEMBL20138441 0.79 PDE2A (0.69) PDE2ARETALDH1A1MAPTXIAP
SCHEMBL20202562 0.79 PDE2A (0.79) PDE2ARETALDH1A1XIAPGHSR
SCHEMBL18282926 0.78 PDE2A (0.76) PDE2ARETGHSRCNR2
SCHEMBL18283165 0.78 PDE2A (0.65) PDE2ARETXIAPGHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180148453-A1 DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148453-A1 DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS PDE12, PDE2A, PDE4D PDE2A 2/4885RET 1879/4885KDM4E 2652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.